The formation of osteoclasts in multiple myeloma bone disease patients involves the secretion of soluble decoy receptor 3

Soluble decoy receptor 3 (DcR3), a member of the tumor necrosis factor receptor superfamily, has recently been reported to increase osteoclast (OC) differentiation. Its impact on the skeleton was reinforced by a study on DcR3 transgenic mice showing a decreased bone mass through the elevation of OC number, providing some initial evidence of DcR3 involvement in bone diseases. In this study we show that malignant plasma cells and T lymphocytes from myeloma patients directly produce DcR3, and this molecule supports the elevated formation of OCs in both peripheral blood and bone marrow from the patients. We also show that serum DcR3 levels in myeloma patients are significantly higher compared to controls.

[1]  G. Mundy,et al.  The pathogenesis of the bone disease of multiple myeloma. , 2008, Bone.

[2]  Wan-Wan Lin,et al.  Attenuation of Bone Mass and Increase of Osteoclast Formation in Decoy Receptor 3 Transgenic Mice* , 2007, Journal of Biological Chemistry.

[3]  J. Chirgwin,et al.  New insights into the role of T cells in the vicious cycle of bone metastases , 2006, Current opinion in rheumatology.

[4]  J. Crowley,et al.  International staging system for multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  A. Zallone,et al.  T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. , 2004, Blood.

[6]  Wan-Wan Lin,et al.  Decoy receptor 3 (DcR3) induces osteoclast formation from monocyte/macrophage lineage precursor cells , 2004, Cell Death and Differentiation.

[7]  Kenneth C. Anderson,et al.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group , 2003, British journal of haematology.

[8]  David L. Lacey,et al.  Osteoclast differentiation and activation , 2003, Nature.

[9]  C. Murphy,et al.  TNFα Potently Activates Osteoclasts, through a Direct Action Independent of and Strongly Synergistic with RANKL. , 2002, Endocrinology.

[10]  S. Takeshita,et al.  TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. , 2000, The Journal of clinical investigation.

[11]  C. Murphy,et al.  TNFalpha potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL. , 2002, Endocrinology.